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de acção dos fármacos anabólicos e dos fármacos anti-reabsortivos e 
os estudos farmacológicos e clínicos efectuados apontam para um pro-
vável benefício para os doentes em usar ambos os agentes de forma 
complementar, isto é, iniciar o tratamento com um anabólico e segui-
damente fazer um anti-reabsortivo.
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Overt hyperthyroidism is a clinical condition caused by exagger-
ated levels of circulating thyroid hormones. Some of its main etio-
logical factors are the hyperfunction of the thyroid gland and the 
iatrogenic cause, like the ministration of excessive doses of thyroid 
hormones. Some studies have shown that the prevalence of hyper-
thyroidism in women aged 65 or more, varies between 5 and 15%. 
The potential risks of hyperthyroidism are diverse and can vary from 
patient to patient; however, heart and bone complications are rela-
tively common, especially among the elderly. Regarding the adult 
skeleton, several anomalies were described, namely reduced bone 
mineral density (BMD) and a higher osteoporotic fracture risk. In-
deed, hyperthyroidism has been recognized to be an important 
cause of secondary osteoporosis and a risk factor for hip fracture in 
women. Moreover, these osteoporotic fractures are associated with 
a risk of precocious mortality, namely in the elderly. In adult life, 
after the acquisition of the peak bone mass, the excess of circulating 
thyroid hormones can lead to an increase in bone resorption, how-
ever, the mechanisms involved in their skeletal action are far from 
totally clarified. While T3 is considered an important regulator of the 
bone tissue integrity and of the bone formation, T4 can stimulate 
directly or indirectly the activity of osteoclasts. Bone remodeling 
accelerates while the bone formation period is decreased, originat-
ing an incomplete substitution with new bone cells and loss of min-
eralized bone. It is estimated that about 10% of mineralized bone is 
loss per cycle. Furthermore, TSH is a negative regulator of bone re-
modeling, inhibiting the formation, the survival of osteoclasts and 
the differentiation of osteoblasts. Recent studies have shown that 
low TSH levels, per se, can lead to osteoporosis and fragility fractures. 
Hypercalcemia, hypercalciuria and a negative balance of calcium 
were also described. The weight loss and the gastrointestinal 
changes (decrease in intestinal calcium absorption and modified vi-
tamin D metabolism) are also associated to the reduction of the body 
lean mass, thus inducing a higher risk of fragility fractures. In old and 
young Portuguese patients with endogenous hyperthyroidism, both 
men and women, significant decreases in the BMD in several skeletal 
regions and an increase in the prevalence of osteoporosis/low BMD 
were observed. Moreover, in young Portuguese men with hyperthy-
roidism, we found a trend for an increase in the prevalence of osteo-
porotic vertebral fractures detected by VFA. In a group of 
postmenopausal women with hyperthyroidism compared to a con-
trol group, we detected a significantly higher prevalence of reduced 
BMD at all skeletal sites and also of osteoporosis. Regarding subclin-
ical hyperthyroidism in postmenopausal women, we found already 
significant correlations not only in bone turnover markers but also 
in some of the hormones implicated in bone metabolism.
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Introduction: The bone strength and fracture risk depend on sev-
eral parameters: macrogeometry of cortical bone, BMD, trabecular 
bone microarchitecture, bone microdamage, bone mineralization, 
and bone metabolism. The trabecular bone score (TBS) of the Ukrain-
ian men with osteoporotic vertebral fractures has not yet been stud-
ied.
Objectives: To evaluate TBS and BMD in men with osteoporotic 
vertebral fractures.
Methods: We’ve examined 243 men aged 30-89 years, divided 
according to the gerontologic classification: 30-44 yrs (n = 46), 45-
59 yrs (n = 83), 60-74 yrs (n = 86), 75-89 yrs (n = 28). The basic group 
consists of 52 men with osteoporotic vertebral fractures in the an-
amnesis (mean age – 59.8 ± 13.7 yrs; mean height – 1.73 ± 6.98 m; 
mean weight – 79.0 ± 14.9 kg) and control group. of 191 men without 
fractures (mean age – 57.4 ± 13.7 yrs; mean height – 1.74 ± 6.89 m; 
mean weight – 76.5 ± 9.3 kg). BMD of PA lumbar spine and proximal 
femur were measured by the DXA method (Prodigy, GEHC Lunar, 
USA) and PA spine TBS were assessed by the TBS iNsight® software 
package installed on DXA machine (Med-Imaps, Pessac, France).
Results: We have observed a significantly lower TBS in the basic 
group (30-44 yrs – 1.083 ± 0.187, 45-59 yrs – 1.025 ± 0.248, 60-74 yrs 
– 1.084 ± 0.170, 75-89 yrs – 0.951 ± 0.170) as compared to the control 
group (30-44 yrs – 1.276 ± 0.121, 45-59 yrs – 1.226 ± 0.156, 60-74 yrs 
– 1.150 ± 0.175, 75-89 yrs – 1.183 ± 0.174); F = 1.56; p < 0.001. We also 
found the lower BMD of lumbar spine in the basic group of patients 
– 30-44 yrs – 0.981 ± 0.125 g/cm2, 45-59 yrs – 1.028 ± 0.184 g/cm2, 
60-74 yrs – 1.014 ± 0.158 g/cm2, 75-89 yrs – 0.970 ± 0.183 g/cm2 
(F = 1.52; p < 0.001) and of the proximal femur – 30-44 yrs – 0.854 ± 
0.149 g/cm2, 45-59 yrs – 0.873 ± 0.139 g/cm2, 60-74 yrs – 0.823 ± 
0.136 g/cm2, 75-89 yrs – 0.716 ± 0.107 g/cm2 (F = 1.10; p < 0.001) com-
pared to the control group.
Conclusions: Subjects with vertebral fractures have TBS and BMD 
parameters significantly lower than the healthy men.
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The complications of diabetes mellitus (DM) and osteoporosis 
may cause severe morbidity and decreased longevity. Osteoporotic 
fractures are common in patients with low bone mineral density or 
with osteoporosis, but in DM the blindness and other eye problems, 
the hypertension, the cardiovascular disease, the amputations and 
other late complications such as chronic renal disease and neuropa-
thy are also common. Bone is a multifunctional tissue with mechan-
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ical, hematopoietic and metabolic tasks that result from the close 
interaction between the osteoblast and the osteoclast. Bone emerged 
lately as an endocrine organ controlling the metabolism of glucose. 
More recently, a special attention has been focused on the os-
teoblasts, osteoclasts and osteocytes functions in people with dia-
betes. Some complications of DM may lead to osteoporotic fractures. 
People affected with type 2 DM have increased fracture risk despite 
higher bone mineral density (BMD), as shown by trabecular bone 
score (TBS) and micro indentation of the tibia tests. Type 2 DM also 
results in an increased risk of fracture and delayed fracture healing. 
Since some years ago, some medications for type 2 diabetes were 
associated with an increase in bone fractures. Poor glycemic control 
in type 2 diabetes is associated with increased risk of fragility frac-
tures. Increased longevity and a lifestyle characterized by low phys-
ical activity and high-energy food intake contribute to an increasing 
incidence of DM and osteoporosis. Both osteoporosis and DM have 
high social and financial costs. Hospital inpatient care, medication 
and supplies, retail prescriptions to treat complications, physician 
office visits and paramedical social assistance have high expendi-
tures. The risk for precocious death among those with diabetes is 
about twice that of people with similar age but without diabetes. So, 
these important public health problems, DM and osteoporosis, are 
two of the leading causes of death. Thus, the bone tissue needs to be 
recognized as another important target among the late diabetic 
complications.
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Introduction: Worldwide, osteoporosis and resulting fractures 
constitute a major public health burden with often devastating con-
sequences, leading to increased levels of morbidity and mortality. 
Determination of molecular genetic causes of osteoporosis is a per-
spective approach. There are several methodologies to assess the 
contribution of a candidate gene in the pathogenesis of osteoporosis. 
One of them consists in determining the correlation between allelic 
polymorphism and candidate factors which cause the disease, which 
in comparison estimates allele frequencies of candidate genes in os-
teoporosis patients with individuals not having the disease and pre-
serving normal bone mineral density.
Objectives: To determine the alleles frequency of genes. regula-
tors of bone metabolism in patients with osteoporosis in Ukrainian 
population, and to assess the contribution of different polymor-
phisms in the risk of developing the disease.
Methods: DNA extraction was performed using the phenol-chlo-
roform method from whole blood. Using PCR followed by restriction 
digestion and visualization of the reaction products in polyacryl-
amide gel have been studied 180 patients with osteoporosis and 
160 healthy people of the same age.
Results: We have found association of polymorphism 60890 A/G 
of vitamin D receptor gene (OR = 3.2 (CI95% 2.2-4.6)) and -234 T/G 
polymorphism of collagen type 1 gene (OR = 2.8 (CI95% 2.1-4.1)) with 
the risk of osteoporosis developing. We have not found association 
of polymorphism -764 T/G of estrogen receptor gene (OR = 1,2 (CI95% 
0.6-2.3)).
Conclusions: Knowing association between pathogenic alleles, 
candidate genes and osteoporosis in Ukrainian population will allow 
to use genetic testing to identify predisposition to the disease. The 
results of this study are important for a more rational organization 
of the prevention and treatment of the illness in the early stages of 
disease development.
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Introduction: Several cardiovascular diseases (hypertension di-
abetes, atherosclerosis, heart failure, and chronic kidney diseases) 
have physiopathology pathways in common with osteoporosis.
Objectives: To evaluate the genetic variation in those pathways 
in association studies of osteoporosis.
Methods: The evaluation of osteoporosis and obesity was done in 650 
subjects after measurement of anthropometric parameters like BMI 
(Kg/m2) and BMD (g/cm2) by DEXA. For the stratification of BMD, densi-
tometry was evaluated with QDR Discovery W and the respective soft-
ware 12.02 (Hologic Inc). Genotyping was performed for SNPs, Ins/Del 
and CNVs with PCR, PCR/RFLPs and PAGE technics. Statistics test were 
done with the used of SPSS programme. The analyses of continuous pa-
rameters and discrete data were employed with the appropriate tests.
Results: We studied variation in genes coding proteins belonging 
to acute phase subsystems (Renin–Angiotensin, Haptoglobin-HFE), 
hormonal systems (CYP1A1-COMT), neurotransmitters (5HTLPR, 
5HTVNTR), transducing signals (ACP1 or LMWPTP) and metabolic 
pathways (MTHFR, GSTM and GSTT).
Conclusions: We observed some involvement of those genetic 
polymorphisms in the susceptibility to osteoporosis and its relation-
ship with the metabolic syndrome, not only of individual genes but 
also for epistasis between them.
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Introduction: Several studies discuss the relationship between 
systemic bone mineral density (BMD) and periodontal diseases. Os-
teoporosis or low systemic BMD should be considered as the risk 
factor for periodontal disease progression.
Objectives: The purpose of this study was to determine the im-
pact of bone metabolism – bone formation, on the periodontal status 
in the patients.
Methods: The study included 72 patients (42 men and 30 women, 
mean age – 45.3 ± 6.2 years) with the healthy periodontal status 
(HPS) and 253 patients (145 men and 108 women, mean age – 45.6 ± 
5.2 years) with generalized periodontitis (GP). Clinical conditions of 
periodontal tissue and radiographic determinations (panoramic 
X-Ray) were evaluated. Skeletal systemic BMD was measured by 
DXA. Metabolic processes of bone tissue were evaluated by bone 
turnover markers: bone tissue formation – osteocalcin (OC), 
bone-specific alkaline phosphatase (BAP) in serum.
Results: Comparative analysis of structural and functional state of 
bone tissue in patients showed a mineral density reduction in GP group 
compared to HPS, but these changes were not statistically significant. 
Disorders of bone tissue metabolism were determined in patients with 
GP. The OC level in the patients with GP (18.89 ± 0.87 ng/ml in men and 
20.39 ± 1.14 ng/ml in women) was statistically significantly (p < 0.01) 
lower compared to the HPS group (24.14 ± 1.04 ng/ml in men and 27.56 
± 1.12 ng/ml in women). Decreased levels of bone formation of biochem-
ical bone remodeling markers (BAP) were found in men (19.21 ± 1,76 U/l) 
and women (22.31 ± 1.65 U/l) GP compared to HPS (25. 21 ± 1.76 U/l in 
men and 29,17 ± 1,13 U/l in women, p < 0.05)
